Yesterday, Hyderabad-based Bharat Biotech published interim results from the Phase 3 trial of it Covid-19 vaccine, branded as Covaxin. 25,8000 subjects participated in the trial. The trial found 43 cases of COVID-19 patients who showed symptoms ranging from mild to moderate and severe, and of the total cases, 36 were from...
Ocugen licenses India’s Covid-19 Vaccine for U.S use
Pennsylvania-based Ocugen just signed an agreement giving in the rights to the Bharat Biotech Covid-19 vaccine candidate, Covaxin, in the United States. Ocugen will be responsible for clinical development, regulatory approval (including Emergency Use Authorization) and commercialization of this Indian vaccine in America. Covaxin is an advanced stage whole-virion inactivated...